[1] Bruton OC.Agammaglobulinemia[J]. Pediatrics, 1952, 9(6):722-728.

[2] Vihinen M, Mattsson PT, Smith CI.Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA)[J]. Frontiers in bioscience : a journal and virtual library, 2000, 5:D917-D928.

[3] Shillitoe BMJ, Gennery AR.An update on X-Linked agammaglobulinaemia: clinical manifestations and management[J]. Current Opinion in Allergy & Clinical Immunology, 2019, 19(6):571-577.

[4] Pac M, Bernatowska EA, Kierkuś J, et al.Gastrointestinal disorders next to respiratory infections as leading symptoms of X-linked agammaglobulinemia in children - 34-year experience of a single center[J]. Archives of medical science : AMS, 2017, 13(2):412-417.

[5] Agarwal S, Cunningham-Rundles C.Gastrointestinal Manifestations and Complications of Primary Immunodeficiency Disorders[J]. Immunology and Allergy Clinics of North America, 2019, 39(1):81-94.

[6] Agarwal S, Mayer L.Diagnosis and treatment of gastrointestinal disorders in patients with primary immunodeficiency[J]. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, 11(9):1050-1063.

[7] Barmettler S, Otani IM, Minhas J, et al.Gastrointestinal Manifestations in X-linked Agammaglobulinemia[J]. Journal of clinical immunology, 2017, 37(3):287-294.

[8] Staines Boone AT, Torres Martínez MG, López Herrera G, et al.Gastric adenocarcinoma in the context of X-linked agammaglobulinemia: case report and review of the literature[J]. Journal of Clinical Immunology, 2014, 34(2):134-137.

[9] van der Meer JW, Weening RS, Schellekens PT, et al.Colorectal cancer in patients with X-linked agammaglo- bulinaemia[J]. Lancet (London, England), 1993, 341 (8858):1439-1440.

[10] Rawat A, Jindal AK, Suri D, et al.Clinical and Genetic Profile of X-Linked Agammaglobulinemia: A Multicenter Experience From India[J]. Frontiers in immunology, 2020, 11:612323.

[11] Singh S, Rawat A, Suri D, et al.X-linked agammaglobulinemia: Twenty years of single-center experience from North West India[J]. Ann Allergy Asthma Immunol, 2016, 117(4):405-411.

[12] Aadam Z, Kechout N, Barakat A, et al.X-Linked Agammagobulinemia in a Large Series of North African Patients: Frequency, Clinical Features and Novel BTK Mutations[J]. J Clin Immunol, 2016, 36(3):187-94.

[13] Pashangzadeh S, Yazdani R, Nazari F, et al.Agammaglo- bulinemia: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management[J]. Endocrine, Metabolic & Immune Disorders Drug Targets, 2020, 20(9):1434-1447.

[14] Cellier C, Foray S, Hermine O.Regional enteritis associated with enterovirus in a patient with X-linked agammaglobulinemia[J]. The New England journal of medicine, 2000, 342(21):1611-1612.

[15] van de Ven AAJM, Hoytema van Konijnenburg DP, Wensing AMJ, et al.The role of prolonged viral gastrointestinal infections in the development of immunodeficiency-related enteropathy[J]. Clinical Reviews In Allergy & Immunology, 2012, 42(1):79-91.

[16] Shillitoe BMJ, Ponsford M, Slatter MA, et al.Haematopoietic Stem Cell Transplant for Norovirus- Induced Intestinal Failure in X-linked Agammaglo- bulinemia[J]. Journal of Clinical Immunology, 2021, 41(7):1574-1581.

[17] Abramowsky CR, Sorensen RU.Regional enteritis-like enteropathy in a patient with agammaglobulinemia: histologic and immunocytologic studies[J]. Human Pathology, 1988, 19(4):483-486.

[18] Hernandez-Trujillo VP, Scalchunes C, Cunningham- Rundles C, et al.Autoimmunity and inflammation in X-linked agammaglobulinemia[J]. Journal of clinical immunology, 2014, 34(6):627-632.

[19] Khan F, Person H, Dekio F, et al.Crohn's-like Enteritis in X-Linked Agammaglobulinemia: A Case Series and Systematic Review[J]. The journal of allergy and clinical immunology In practice, 2021, 

doi:10.1016/j.jaip.2021.04.070.

[20] Renzi S, Langenberg-Ververgaert KPS, Waespe N, et al.Primary immunodeficiencies and their associated risk of malignancies in children: an overview[J]. European Journal of Pediatrics, 2020, 179(5):689-697.

[21] Lederman HM.Cancer in children with primary or secondary immunodeficiencies[J]. The Journal of Pediatrics, 1995, 127(2):335.

[22] Flynn S, Eisenstein S.Inflammatory Bowel Disease Presentation and Diagnosis[J]. The Surgical Clinics of North America, 2019, 99(6):1051-1062.

[23] Albshesh A, Eder P, Ribaldone DG, et al.Primary Hypogammaglobulinaemia with Inflammatory Bowel Disease-Like Features: An ECCO CONFER Multicentre Case Series[J]. Journal of Crohn's & Colitis, 2022, 16(1):91-97.

[24] Washington K, Stenzel TT, Buckley RH, et al.Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglo- bulinemia[J]. The American Journal of Surgical Pathology, 1996, 20(10):1240-1252.

[25] Maarschalk-Ellerbroek LJ, Oldenburg B, Mombers IMH, et al.Outcome of screening endoscopy in common variable immunodeficiency disorder and X-linked agammaglo- bulinemia[J]. Endoscopy, 2013, 45(4): 320-323.

[26] Okumura R, Takeda K.Roles of intestinal epithelial cells in the maintenance of gut homeostasis[J]. Experimental & Molecular Medicine, 2017, 49(5):e338.

[27] Okumura R, Takeda K.Maintenance of gut homeostasis by the mucosal immune system[J]. Proceedings of the Japan Academy Series B, Physical and Biological Sciences, 2016, 92(9):423-435.

[28] Brunner C, Müller B, Wirth T.Bruton's Tyrosine Kinase is involved in innate and adaptive immunity[J]. Histology and Histopathology, 2005, 20(3):945-955.

[29] Guan D, Wang Z, Huo J, et al.Bruton's tyrosine kinase regulates gut immune homeostasis through attenuating Th1 response[J]. Cell Death & Disease, 2021, 12(5):431.

[30] Bao Y, Zheng J, Han C, et al.Tyrosine kinase Btk is required for NK cell activation[J]. The Journal of Biological Chemistry, 2012, 287(28):23769-23778.

[31] Mao L, Kitani A, Hiejima E, et al.Bruton tyrosine kinase deficiency augments NLRP3 inflammasome activation and causes IL-1β-mediated colitis[J]. The Journal of Clinical Investigation, 2020, 130(4):1793-1807.

[32] Taneichi H, Kanegane H, Sira MM, et al.Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked agammaglobulinemia[J]. Clinical Immunology (Orlando, Fla), 2008, 126(2):148-154.

[33] Shelyakin PV, Lupyr KR, Egorov ES, et al.Naïve Regulatory T Cell Subset Is Altered in X-Linked Agammaglobulinemia[J]. Frontiers in immunology, 2021, 12:697307.

[34] Zhang Y-Z, Li Y-Y.Inflammatory bowel disease: pathogenesis[J]. World Journal of Gastroenterology, 2014, 20(1):91-99.

[35] Maffeis M, Notarangelo LD, Schumacher RF, et al.Primary Immunodeficiencies and Oncological Risk: The Experience of the Children's Hospital of Brescia[J]. Frontiers In Pediatrics, 2019, 7:232.

[36] Messex JK, Liou G-Y.Targeting BTK Signaling in the Microenvironment of Solid Tumors as a Feasible Cancer Therapy Option[J]. Cancers, 2021, 13(9).

[37] Pal Singh S, Dammeijer F, Hendriks RW.Role of Bruton's tyrosine kinase in B cells and malignancies[J]. Molecular Cancer, 2018, 17(1):57.

[38] Uckun FM, Venkatachalam T.Targeting Solid Tumors With BTK Inhibitors[J]. Frontiers In Cell and Developmental Biology, 2021, 9:650414.

[39] Coussens LM, Werb Z.Inflammation and cancer[J]. Nature, 2002, 420(6917):860-867.

[40] Wiesik-Szewczyk E, Sołdacki D, Paczek L, et al.Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies[J]. Frontiers In Immunology, 2020, 11:981.

[41] Bonagura VR, Marchlewski R, Cox A, et al.Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection[J]. The Journal of Allergy and Clinical Immunology, 2008, 122(1):210-212.

[42] Jasion VS, Burnett BP.Survival and digestibility of orally-administered immunoglobulin preparations containing IgG through the gastrointestinal tract in humans[J]. Nutrition Journal, 2015, 14:22.

[43] Schwimmer D, Glover S.Primary Immunodeficiency and the Gut[J]. Gastroenterology Clinics of North America, 2019, 48(2):199-220.

[44] D'Amico F, Fiorino G, Peyrin-Biroulet L, et al. Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing[J]. Immunotherapy, 2019, 11(7):565-575.

[45] Davey PT, Tan CJ, Gardiner K.The use of infliximab in X-linked agammaglobulinaemia associated enteropathy[J]. Annals of the Royal College of Surgeons of England, 2014, 96(5):e5-e6.

[46] Cekic S, Ozgur T, Karali Y, et al.Vedolizumab treatment in a patient with X-linked agammaglobulinemia, is it safe and efficient?[J]. Turk J Pediatr, 2019, 61(6):937-940.

[47] King JR, Grover Z, Irani N, et al.Vedolizumab is safe and effective in the treatment of X-linked agammaglo- bulinemia-associated inflammatory bowel disease[J]. The journal of allergy and clinical immunology In practice, 2021, 9(2):1006-1007.

[48] Bryan BA, Battersby A, Shillitoe BMJ, et al.Respiratory Health and Related Quality of Life in Patients with Congenital Agammaglobulinemia in the Northern Region of the UK[J]. Journal of Clinical Immunology, 2016, 36(5):472-479.

[49] Gray DH, Villegas I, Long J, et al.Optimizing Integration and Expression of Transgenic Bruton's Tyrosine Kinase for CRISPR-Cas9-Mediated Gene Editing of X-Linked Agammaglobulinemia[J]. The CRISPR journal, 2021, 4(2):191-206.

[50] Hermaszewski RA, Webster AD.Primary hypogammaglo- bulinaemia: a survey of clinical manifestations and complications[J]. The Quarterly journal of medicine, 1993, 86(1):31-42.

[51] Moreau T, Calmels B, Barlogis V, et al.Potential application of gene therapy to X-linked agammaglo- bulinemia[J]. Current Gene Therapy, 2007, 7(4):284-294.